Bevacizumab biosimilar is under clinical development by Essex Bio-Technology and currently in Phase III for Wet (Neovascular / Exudative) Macular Degeneration. According to GlobalData, Phase III drugs for Wet (Neovascular / Exudative) Macular Degeneration have a 72% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Bevacizumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bevacizumab biosimilar overview
Bevacizumab (Hanbeitai) is a recombinant humanized monoclonal IgG1 antibody, acts as an anti-neoplastic agent. It is formulated as solution for intravenous route of administration. Hanbeitai is indicated for the treatment of metastatic colorectal cancer (mCRC) and unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer (nsNSCLC). It is under development for solid tumors, hepatocellular carcinoma, diabetic retinopathy and wet age-related macular degeneration, cervical cancer and epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer. It was also under development for the treatment of metastatic hepatocellular carcinoma.
Essex Bio-Technology overview
Essex Bio-Technology (Essex) is a biopharmaceutical company that manufactures and markets biopharmaceutical products. The company provides basic fibroblast growth factor series and other ophthalmic drugs. Its (basic fibroblast growth factor (bFGF)series products comprise beifushu eye drops, beifushu gel, beifuji spray, beifuji lyophiliaed powder and beifuxin gel. Essex has developed manufacturing technology for fermentation of rb-bFGF and rh-bFGF engineering bacteria, and the separation and purification of proteins. It also offers products such as ophthalmic drugs and surgicals. Essex brands include Beifuji, Beifushu, Beifuxin, Xalacom, Adv. Dental and other brands. It offers products for treating a wide range of therapeutic areas, which include ophthalmology, dermatology and wound healing. The company operates in Hong Kong and China. Essex is headquartered in Hong Kong.
For a complete picture of Bevacizumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
